dimethyl 2-amino-5-bromoterephthalate | 185051-42-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: dimethyl 2-amino-5-bromoterephthalate
• 英文别名: 6-amino-4-bromo-terephthalic acid dimethyl ester；2-amino-5-bromoterephthalate dimethyl ester；2-amino-5-bromo-terephthalic acid dimethyl ester；dimethyl 2-amino-5-bromobenzene-1,4-dicarboxylate
• CAS: 185051-42-7
• 化学式: C₁₀H₁₀BrNO₄
• 分子量: 288.098
• InChiKey: BYLKMWOSPVNYPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  78.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2922499990

反应信息

• 作为反应物：
  描述：

  dimethyl 2-amino-5-bromoterephthalate 在 盐酸 、 palladium diacetate 、 lithium hydroxide 、 硼烷四氢呋喃络合物 、 四溴化碳 、 sodium carbonate 、 三苯基膦 、 sodium nitrite 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 丙酮 、 甲苯 为溶剂， 反应 94.5h， 生成 2-(2-methylphenyl)-4-bromomethyl-5-iodobenzoic acid methyl ester
  参考文献：
  名称：

  Second-Generation Peptidomimetic Inhibitors of Protein Farnesyltransferase Demonstrating Improved Cellular Potency and Significant in Vivo Efficacy

  摘要：

  The synthesis and evaluation of analogues of previously reported farnesyltransferase inhibitors, pyridyl benzyl ether 3 and pyridylbenzylamine 4, are described. Substitution of 3 at the 5-position of the core aryl ring resulted in inhibitors of equal or less potency against the enzyme and decreased efficacy in a cellular assay against Ras processing by the enzyme. Substitution of 4 at the benzyl nitrogen yielded 26, which showed improved efficacy and potency and yet presented a poor pharmacokinetic profile. Further modification afforded 30, which demonstrated a dramatically improved pharmacokinetic profile. Compounds 26 and 29 demonstrated significant in vivo efficacy in nude mice inoculated with MiaPaCa-2, a human pancreatic tumorderived cell line.

  DOI：

  10.1021/jm9901935
• 作为产物：
  描述：

  2-氨基对苯二甲酸二甲酯 在 溴 作用下， 以 二氯甲烷 为溶剂， 以81%的产率得到dimethyl 2-amino-5-bromoterephthalate
  参考文献：
  名称：

  [DE] NEUE SUBSTITUIERTE STICKSTOFFHALTIGE HETEROBICYCLEN UND DEREN VERWENDUNG ALS FAKTOR XA INHIBITOREN
  [EN] NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS
  [FR] NOUVEAUX COMPOSES HETEROBICYCLIQUES AZOTES SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DU FACTEUR XA

  摘要：

  本发明涉及一种新的取代的含氮杂双环化合物，其一般式为（I），其中B，X1至X3和R1至R5如权利要求1所定义，其互变异构体，对映异构体，顺反异构体，混合物和盐，特别是与无机或有机酸或碱的生理相容性盐，具有有价值的特性。上述一般式（I）化合物及其互变异构体，对映异构体，顺反异构体，混合物和盐，特别是与无机或有机酸或碱的生理相容性盐，以及其立体异构体具有有价值的药理特性，特别是抗血栓作用和Xa因子抑制作用。

  公开号：

  WO2004058743A1

文献信息

• Inhibitors of protein isoprenyl transferases
  申请人：University of Pittsburgh

  公开号：US20020193596A1

  公开（公告）日：2002-12-19

  Compounds having the formula 1 or a pharmaceutically acceptable salt thereof wherein R 1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L 2 —, and (i) heterocyclic-L 2 —; R 2 is selected from (a) 2 (b) —C(O)NH—CH(R 14 )—C(O)OR 15 , (c) 3 (d) —C(O)NH—CH(R 14 )—C(O)NHSO 2 R 16 (e) —C(O)NH—CH(R 14 )-tetrazolyl, (f) —C(O)NH-heterocyclic, and (g) —C(O)NH—CH(R 14 )—C(O)NR 17 R 18 ; R 3 is heterocyclic, aryl, substituted or unsubstituted cycloalkyl; R 4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L 1 is absent or is selected from (a) —L 4 —N(R 5 )—L 5 —, (b) —L 4 —O—L 5 —, (c) —L 4 —S(O) n —L 5 — (d) —L 4 -L 6 —C(W)—N(R 5 )—L 5 —, (e) —L 4 -L 6 —S(O) m —N(R 5 )—L 5 —, (f) —L 4 —N(R 5 )—C(W)—L 7 -L 5 —, (g) —L 4 —N(R 5 )—S(O) p —L 7 —L 5 —, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, and (j) optionally substituted alkynylene are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.

  具有以下公式的化合物或其药学上可接受的盐，其中R1为(a)氢，(b)较低的烷基，(c)烯基，(d)烷氧基，(e)硫代烷氧基，(f)卤素，(g)卤代烷基，(h)芳基-L2—，以及(i)杂环-L2—；R2从(a)中选择，(b) -C(O)NH-CH(R14)-C(O)OR15，(c)中选择，(d) -C(O)NH-CH(R14)-C(O)NHSO2R16，(e) -C(O)NH-CH(R14)-四唑基，(f) -C(O)NH-杂环，以及(g) -C(O)NH-CH(R14)-C(O)NR17R18；R3为杂环，芳基，取代或未取代的环烷基；R4为氢，较低烷基，卤代烷基，卤素，芳基，芳基烷基，杂环基，或(杂环)烷基；L1为空缺或从(a) -L4-N(R5)-L5-，(b) -L4-O-L5-，(c) -L4-S(O)n-L5-，(d) -L4-L6-C(W)-N(R5)-L5-，(e) -L4-L6-S(O)m-N(R5)-L5-，(f) -L4-N(R5)-C(W)-L7-L5-，(g) -L4-N(R5)-S(O)p-L7-L5-，(h)可选择取代的烷基，(i)可选择取代的烯基，以及(j)可选择取代的炔基是蛋白异戊二烯转移酶的抑制剂。还公开了蛋白异戊二烯转移酶抑制组合物和抑制蛋白异戊二烯转移酶的方法。
• ASK1 INHIBITOR COMPOUNDS AND USES THEREOF
  申请人：Seal Rock Therapeutics, Inc.

  公开号：US20180291002A1

  公开（公告）日：2018-10-11

  Described herein are compounds, including pharmaceutically acceptable salts, solvates, metabolites, prodrugs thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.

  本发明涉及化合物，包括药物可接受的盐、溶剂化物、代谢物、前药等，以及制造这些化合物的方法，包含这些化合物的药物组合物，以及使用这些化合物治疗非酒精性脂肪肝炎和其他以组织修复功能异常和纤维化为特征的疾病的方法。
• Metal-Organic Framework Regioisomers Based on Bifunctional Ligands
  作者：Min Kim、Jake A. Boissonnault、Phuong V. Dau、Seth M. Cohen

  DOI：10.1002/anie.201106429

  日期：2011.12.16

  Regioisomeric MOFs: A series of bifunctional metal–organic framework (MOF) regioisomers has been produced from amino‐halo benzene dicarboxylate (NH2X‐BDC) ligands. ZrIV‐ and ZnII‐based MOFs were synthesized and for the flexbile ZnII‐based MOFs, gas sorption properties were dependent on the ligand substitution pattern.

  区域异构MOF：从氨基卤代苯二羧酸盐（NH 2 X-BDC）配体产生了一系列双功能金属-有机骨架（MOF）区域异构体。合成了基于Zr IV和Zn II的MOF，对于基于柔性Zn II的MOF，气体吸附性能取决于配体取代方式。
• ISOINDOLONES DERIVATIVES AS MEK KINASE INHIBITORS AND METHODS OF USE
  申请人：Gancia Emanuela

  公开号：US20110124622A1

  公开（公告）日：2011-05-26

  The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  本发明涉及公式（I）的异吲哚酮，具有抗癌和/或抗炎活性，更具有MEK激酶抑制活性。本发明提供了用于抑制异常细胞生长，治疗增生性疾病或治疗哺乳动物炎症性疾病的组合物和方法。本发明还涉及使用该化合物进行哺乳动物细胞的体外，体内和原位诊断或治疗，或相关病理条件的方法。
• Isoindolones derivatives as MEK kinase inhibitors and methods of use
  申请人：Gancia Emanuela

  公开号：US08492427B2

  公开（公告）日：2013-07-23

  The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

  该发明涉及具有抗癌和/或抗炎活性的公式（I）的异吲哚酮，更具体地涉及MEK激酶抑制活性。该发明提供了用于抑制异常细胞生长、治疗增生性疾病或治疗哺乳动物的炎症性疾病的组合物和方法。该发明还涉及使用该化合物进行哺乳动物细胞的体外、体内诊断或治疗，或相关病理条件的方法。